Initial combination therapy for rapid and effective control of moderate and severe hypertension

Journal of Human Hypertension

Volumn 23, Issue 1, 2009, Pages 4-11

  Franklin, S S ^a   Neutel, J M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Orange County Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY; HUMAN; HYPERTENSION; MONOTHERAPY; PRACTICE GUIDELINE; PUBLIC HEALTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG THERAPY, COMBINATION; GUIDELINES AS TOPIC; HUMANS; HYPERTENSION; SEVERITY OF ILLNESS INDEX;

EID: 57749202460     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.72     Document Type: Review

References (68)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
4. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M et al Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313.
5. Preston RA, Baltodano NM, Cienki J, Materson BJ. Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. J Hum Hypertens 1999; 13: 249-255.
6. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension 1996; 27: 144-147.
7. Franklin S, Lapuerta P, Cox D, Donovan M. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: An analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens 2007; 9: 15-22.
8. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet 1978; 2: 1139-1141.
9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
10. VA Cooperative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129mmHg. JAMA 1967; 202: 1028-1034.
11. Veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mmHg. JAMA 1970; 213: 1143-1152.
12. Wolff FW, Lindeman RD. Effects of treatment in hypertension. Results of a controlled study. J Chronic Dis 1966; 19: 227-240.
13. Bender SR, Fong MW, Heiz S, Bisognano JD. Characteristics and management of patients presenting to the emergency department with hypertensive urgency. J Clin Hypertens 2006; 8: 12-18.
14. Karras DJ, Kruus LK, Cienki JJ, Wald MM, Chiang WK, Shayne P et al Evaluation and treatment of patients with severely elevated blood pressure in academic emergency departments: A multicenter study. Ann Emerg Med 2006; 47: 230-236.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
16. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
17. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
18. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 765-774.
19. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
20. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
21. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A.
22. Drexler H. Factors involved in the maintenance of endothelial function. Am J Cardiol 1998; 82: 3S-4S.
23. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474.
24. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
25. Nesbitt SD, Julius S. Prehypertension: A possible target for antihypertensive medication. Curr Hypertens Rep 2000; 2: 356-361.
26. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
27. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Co ll Cardiol 1996; 27: 1214-1218.
28. Wolff FW, Lindeman RD. Effects of treatment in hypertension. Results of a controlled study. J Chronic Dis 1966; 19: 227-240.
29. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28(Suppl 1): S4-S36.
30. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL et al Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.
31. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156 1969-1978.
32. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
33. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
34. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
35. Bakris G, Hill M, Mancia G, Steyn K, Black HR, Pickering T et al. Achieving blood pressure goals globally: Five core actions for health-care professionals. Aworldwide call to action. J Hum Hypertens 2008; 22: 63-70.
36. Bramlage P. Clinical practice and recent recommendations in hypertension management - reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin 2007; 23(4): 783-791.
37. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1963.
38. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413-420.
39. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
40. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361 117-124.
41. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
42. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 2005; 365: 939-946.
43. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
44. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
45. O'Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E et al. Effect of candesartan on New York Heart Association functional class. Results of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 2004; 25: 1920-1926.
46. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a North of Sweden efficacy evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
47. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290.
48. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27: S15-S35.
49. Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press 2007; 16: 2379-2386.
50. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K et al Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597.
51. Bakris G, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303-1309.
52. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial. J Clin Hypertens 2005; 7: 578-586.
53. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens 2006; 8: 850-857.
54. ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008; 358: 1547-1559.
55. Malacco E, Santonastaso M, Varí NA, Gargiulo A, Spagnuolo V, Bertocchi F et al. Comparison of valsartan 160mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatments of hypertension: The Blood Pressure Reduction and Tolerability in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004; 26: 855-865.
56. Neutel JM, Smith DH. Improving patient compliance: A major goal in the management of hypertension. J Clin Hypertens 2003; 5: 127-132.
57. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9: 2-6.
58. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002; 62: 443-462.
59. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1: 43-50.
60. Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. J Clin Hypertens 2007; 9: 23-30.
61. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805.
62. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003; 326: 1427.
63. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andréjak M et al Comparison of different therapeutic strategies in hypertension: A low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004; 22 2379-2386.
64. Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens 2004; 6: 614-620.
65. Fox JC, Leight K, Sutradhar SC, Demopoulos LA, Gleim GW, Lewin AJ et al. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: A double-blind trial of initial monotherapy vs combination therapy. J Clin Hypertens 2004; 6: 437-442.
66. Lacourciere Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallelgroup trial. Clin Ther 2005; 27: 1013-1021.
67. Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22: 266-274.
68. Franklin S, Lapuerta P, Bhaumik A, Ptaszynska A. Rapid blood pressure reduction with irbesartan/HCTZ as a first-line treatment of severe hypertension - a timepoint analysis. J Hypertens 2006; 24: S284-S285.